Sanara Medtech Inc. · NASDAQ:SMTI
Sanara Medtech — Q1 2024 Earnings Presentation
11 slides from Sanara Medtech's earnings presentation, May 14, 2024
Slide 1: Q1 2024 Earnings and Business Update Call
Q1 2024 Earnings and Business Update Call May 14, 2024
Slide 2: Disclaimers
Disclaimers This presentation contains forward-looking statements that discuss expectations as to future trends, plans, events, results of operations or financial condition, or state other information relating to Sanara MedTech Inc. (the “Company,” “Sanara,” “we,” “our” or “us”). All statements othe
Slide 3: Executive Summary
Executive Summary • CEO • Former CEO Zach Fleming resigned on May 10, 2024, and Ron Nixon has been appointed CEO by the Company’s Board of Directors. • Financial Update • Highest net revenue quarter in the Company’s history ($18.5 million) • Tenth consecutive record revenue quarter • Net loss of $1.
Slide 4: Surgical Sales
Surgical Sales Sales Overview (Unaudited) • Sanara products were sold in over 1,080 hospitals/ASCs across 34 states plus the District of Columbia(1) in the TTM • Sanara products were contracted or approved to be sold in more than 3,000 hospitals/ASCs as of March 31, 2024. • BIASURGE® sales and hospi
Slide 5: CRG Facility
CRG Facility Strategic Rationale • Non-dilutive to equity holders and it provides growth/acquisition capital as well as strengthens our cash position. • Flexible capital that can be drawn at the Company’s option. • Allows for Sanara to enter into a separate $10.0 million revolver backed by A/R and i
Slide 6: Q1 2024 Financial Highlights
Q1 2024 Financial Highlights • Revenue • For the three months ended March 31, 2024, Sanara generated net revenue of $18.5 million compared to net revenue of $15.5 million for the three months ended March 31, 2023, a 19% increase from the prior year period. • The higher net revenue for the three mont
Slide 7: Q1 2024 Financial Highlights (Continued)
Q1 2024 Financial Highlights (Continued) • R&D Expenses • R&D expenses for the three months ended March 31, 2024, were $0.9 million compared to $1.3 million for the three months ended March 31, 2023. • The lower R&D expenses for the three months ended March 31, 2024 compared to the three months ende
Slide 8: Questions
Questions Evidence Based Healing
Slide 9: Appendix
Appendix . Sanara “~ MedTech Evidence Based Healing
Slide 10: Non-GAAP Financial Measure
Non-GAAP Financial Measure Use of Non-GAAP Financial Measure To supplement the Company’s financial information presented in accordance with generally accepted accounting principles in the United States (“GAAP”), we present certain non-GAAP financial measures in this press release and on the related
Slide 11: Reconciliation of GAAP to Non-GAAP Financial Measures
Reconciliation of GAAP to Non-GAAP Financial Measures Reconciliation of Net Loss to Adjusted EBITDA (Unaudited): Three Months Ended March 31, 2024 2023 Net Loss $ (1,764,184) $ (1,177,900) Adjustments Interest expense and other 267,336 6 Depreciation and amortization 1,105,420 778,875 Noncash share-